Manufacturer
INTAS PHARM LTD
Contents
Epirubicin HCl
Indication
Breast, gastric, ovarian & small cell lung cancer; non-Hodgkin's lymphoma; advanced/metastatic soft tissue sarcoma; superficial bladder cancer (Tis; Ta). Prophylaxis of recurrence after transurethral resection of stage T1 papillary cancer & stage Ta multifocal papillary cancer (grade 2 & 3).
Instruction
Adult Monotherapy: 60-90 mg/m2 dose/cycle. Previously untreated small cell lung cancer 120 mg/m2 on day 1 every 3 wk. Previously untreated squamous large cell & adenocarcinoma 135 mg/m2 on day 1 or 45 mg/m2 on days 1, 2, 3 every 3 wk. Breast cancer 35 mg/m2 as single agent & 120 mg/m2 in combination every 3-4 wk. Adjuvant treatment of early breast cancer w/ +ve lymph nodes 100-120 mg/m2 every 3-4 wk. Superficial bladder tumors 8 wkly instillations of 50 mg. Chemical cystitis Reduce dose to 30 mg. In situ carcinoma Increase dose to 80 mg. Prophylaxis of recurrences after transurethral resection of superficial tumors 4 wkly administrations of 50 mg followed by 11 mthly instillations.
Drug interaction
Higher risk of heart failure w/ high dose cyclophosphamide or 5-fluorouracil. Additive cardiotoxic effect w/ propranolol. Enhanced myocardial toxicity w/ concurrent mediastinal radiotherapy. Not recommended to mix w/ other antitumour agents in same container. Incompatible w/ heparin.
Malaysia
